William Oh, MD Email William Oh
-
- Positions
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Urology
-
- Specialties
- Cancer (Oncology)
- Hematology-Oncology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- Ruttenberg Treatment Center 212-241-6756 212-241-6756
Book an Appointment - William Oh, MD
William K. Oh, MD, an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers, is Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute, an NCI-designated cancer center, at the Icahn School of Medicine at Mount Sinai. He is also Professor of Medicine, and Urology, and is the Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics.
Dr. Oh’s research interests include novel biomarkers and therapeutics in advanced prostate cancer. In addition to serving as the Principal Investigator of multiple clinical trials in prostate cancer, he has developed large clinical databases and specimen repositories for genitourinary cancers at both Harvard Medical School and the Dana-Farber Cancer Institute and at Mount Sinai, which have enrolled more than 10,000 patients with prostate, renal, and bladder cancer.
Dr. Oh has authored more than 300 articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer. In addition to reviewing for top journals such as The New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh co-edits “Testicular Cancer” for Up to Date and is Associate Editor of CA: A Cancer Journal for Clinicians. He is a member of the prestigious American Society for Clinical Investigation and has been repeatedly selected as a Top Doctor in New York magazine, Castle Connolly, Best Doctors, and Super Doctors over the past decade.
Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston. He then completed a fellowship in medical oncology at the Dana-Farber Cancer Institute in 1997.
Prior to joining Mount Sinai in 2009, Dr. Oh served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center.
In the News
Watch Dr. Oh discuss Advanced Prostate Cancer Care on WebMD.com.
Read about Dr. Oh in the NY Daily News "Daily Checkup"column -
"Men's age old problem: Prostate cancer hits many, but screening and new treatments lessen the danger"PDF version: "Men's age old problem: Prostate cancer hits many, but screening and new treatments lessen the danger"
Certification
Medical Oncology
Clinical Focus
- Adrenal Cortical Carcinoma
- Bladder Cancer
- Kidney Cancer
- Prostate Cancer
- Testicular Tumors
- Urologic Cancers
Education
MD, New York University School of Medicine
Residency, General Medicine
Brigham and Women's Hospital, Harvard Medical School
Fellowship, Medical Oncology
Dana Farber Cancer Institute
Language
English
2011
American Society of Clinical Investigation
2010-18
New York Magazine Best Doctors
2009-18
New York Super Doctors
2008-18
America’s Top Doctors for Cancer (Castle Connolly)
2007-8
Harvard Business School Physician Leadership Program
2003-18
Best Doctors in America
2003
Compassionate Caregiver of the Year, Kenneth B. Schwartz Center, Honorable Mention
1992
Alpha Omega Alpha
1992
Prize in Internal Medicine, NYU School of Medicine
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Oh during 2018 and/or 2019. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Bellicum Pharmaceuticals, Inc.
- Diversified Management Inc.
- Gerson Lehrman Group
- Jeffries & Co.
- iCeutica
- sanofi-aventis
Scientific Advisory Board:
- Active Biotech
- Amgen Inc.
- Astellas Pharma Inc.
- Bayer
- Dendreon Corporation
- Janssen Biotech, Inc., formerly Centocor Biotech, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.